Comprehensively mapping and decoding the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
Comprehensively mapping and decoding the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes
Founded: December 2018
Headquarters: New York, NY
Core offering: Single-cell multiomic immune mapping + ML platform (AMICA) for therapeutic discovery
Total funding: USD 295,000,000
Immune system mapping to improve discovery and development of immunology and oncology therapeutics.
2018
Biotechnology Research
USD 20,000,000
USD 60,000,000
Raised to expand annotated multi-omic immune cell atlas; reported total after round > USD 80M
USD 215,000,000
Brought reported total funding to USD 295M
“Includes strategic and institutional investors such as Schusterman Family Investments, Catalio Capital Management, Viola/TLV, Piedmont Capital Investments, and Alexandria Venture Investments.”
| Company |
|---|
 |
 |
 |
 |
 |